Genscript Biotech Corporation (G51) — Cash Flow Reinvestment Rate
Genscript Biotech Corporation (G51) has a Cash Flow Reinvestment Rate of 0.00x as of December 2019, reinvesting €0.00 (capex €0.00 ) from operating cash flow of €61.62 Million. See Genscript Biotech Corporation (G51) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Genscript Biotech Corporation Cash Flow Reinvestment Rate (2016–2025)
Historical reinvestment intensity for Genscript Biotech Corporation across 5 annual periods. For the full cash flow conversion analysis, see G51 cash generation efficiency.
Annual Cash Flow Reinvestment Rate for Genscript Biotech Corporation (2016–2025)
Year-by-year capital reinvestment analysis for Genscript Biotech Corporation. See Genscript Biotech Corporation free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.45x | €147.45 Million | €325.52 Million | €83.84 Million | ▼ -96.4% |
| 2024 | 12.49x | €945.21 Million | €75.65 Million | €147.92 Million | ▲ +2502.3% |
| 2018 | 0.48x | €147.72 Million | €307.66 Million | €70.84 Million | ▼ -69.9% |
| 2017 | 1.60x | €34.09 Million | €21.37 Million | €29.21 Million | ▲ +206.9% |
| 2016 | 0.52x | €17.30 Million | €33.27 Million | €8.98 Million | — |